FDA accepts Roche unit Genentech vamikibart filing for uveitic macular edema treatment

• Roche unit Genentech won FDA acceptance of its BLA for vamikibart to treat uveitic macular edema.
• The agency set a target decision date of July 2027.
• Regulatory filings were also accepted in the EU, China, Japan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20261010064674) on October 10, 2026, and is solely responsible for the information contained therein.